Login to Your Account

Clinic Roundup

Thursday, November 8, 2012

Moberg Derma AB, of Stockholm, Sweden, said it received the final results from a Phase II study of MOB-015 in patients with onychomycosis and, because the clinical efficacy was unsatisfactory, said it decided to initiate a new study with an improved formulation. The new trial, set to enroll 35 patients, will start in December.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription